UK football captain diagnosed with acute myeloid leukemia

Stiliyan Petrov, captain of the UK football club Aston Villa, has been diagnosed with acute myeloid leukemia. The Bulgarian national is just 32 years old.

According to the Telegraph, Petrov developed a fever last week. After undergoing a bone marrow scan, the team's medical staff made the diagnosis. He has already chemotherapy treatments, which together with standard care will likely require several months to complete.

At that age, Petrov is extraordinarily young to have received this diagnosis, joining no more than about 200 people per year in the United Kingdom that age with the same diagnosis. Typically, AML is diagnosed in people over the age of 60, and is often a disease that has transformed from MDS, or myelodysplastic syndromes.

Acute myeloid leukemia is considered a curable disease, but in order to have a chance at cure the disease generally must be caught early. Furthermore, the patient's age and general health prior to developing the disease weighs heavily on prognosis. Thus experts consulted by the Telegraph believe Petrov's chances are good at a full recovery.

Source: The Telegraph

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap